



**Press Release**  
October 4, 2012  
Gothenburg

## **Shares in Xvivo Perfusion AB will begin trading on NASDAQ OMX First North on October 8, 2012**

Xvivo Perfusion AB was spun off from Vitrolife AB on October 1, whereby Vitrolife shareholders received one share in Xvivo Perfusion for each share in Vitrolife. Xvivo Perfusion shares have been approved for trade on NASDAQ OMX First North and the first day for trade will be October 8.

In view of the listing on First North, Xvivo Perfusion is today publishing a company description that is available on the company's website. The company description (in Swedish) is also available at Vitrolife's webpage [www.vitrolife.com/corporate](http://www.vitrolife.com/corporate).

October 4, 2012

VITROLIFE AB (publ)  
Thomas Axelsson  
CEO

### **Queries should be addressed to:**

Thomas Axelsson, CEO, phone +46 31 721 80 01  
Mikael Engblom, CFO, phone +46 31 721 80 14

---

Vitrolife is a global biotechnology/medical device Group. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

---

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.  
Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Website: [www.vitrolife.com](http://www.vitrolife.com)

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 4, 2012 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.